- Home
- JYD vs RNXT Comparison
JYD vs RNXT Comparison
Compare JYD & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JYD
- RNXT
- Stock Information
- Founded
- JYD 2001
- RNXT 2012
- Country
- JYD China
- RNXT United States
- Employees
- JYD N/A
- RNXT N/A
- Industry
- JYD Oil Refining/Marketing
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- JYD Consumer Discretionary
- RNXT Health Care
- Exchange
- JYD Nasdaq
- RNXT Nasdaq
- Market Cap
- JYD 21.0M
- RNXT 21.6M
- IPO Year
- JYD 2023
- RNXT 2021
- Fundamental
- Price
- JYD $0.99
- RNXT $1.41
- Analyst Decision
- JYD
- RNXT Strong Buy
- Analyst Count
- JYD 0
- RNXT 2
- Target Price
- JYD N/A
- RNXT $6.13
- AVG Volume (30 Days)
- JYD 65.1K
- RNXT 57.0K
- Earning Date
- JYD 12-06-2024
- RNXT 11-13-2024
- Dividend Yield
- JYD N/A
- RNXT N/A
- EPS Growth
- JYD N/A
- RNXT N/A
- EPS
- JYD N/A
- RNXT N/A
- Revenue
- JYD $82,427,232.00
- RNXT N/A
- Revenue This Year
- JYD N/A
- RNXT N/A
- Revenue Next Year
- JYD N/A
- RNXT N/A
- P/E Ratio
- JYD N/A
- RNXT N/A
- Revenue Growth
- JYD 63.05
- RNXT N/A
- 52 Week Low
- JYD $0.42
- RNXT $0.53
- 52 Week High
- JYD $3.10
- RNXT $2.35
- Technical
- Relative Strength Index (RSI)
- JYD 51.24
- RNXT 78.92
- Support Level
- JYD $0.93
- RNXT $1.08
- Resistance Level
- JYD $1.10
- RNXT $1.58
- Average True Range (ATR)
- JYD 0.12
- RNXT 0.12
- MACD
- JYD -0.00
- RNXT 0.03
- Stochastic Oscillator
- JYD 58.33
- RNXT 67.54
About JYD Jayud Global Logistics Limited
Jayud Global Logistics Ltd is a end-to-end supply chain solution providers in China, with a focus on providing cross-border logistics services. It offers freight forwarding services, (ii) supply chain management, and (iii) other value-added services.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.